loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 32140 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Minakem (formerly Delmar Chemicals)

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    PharmaCompass Sponsored Ads

    Aspen API. More than just an API.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Minakem (formerly Delmar Chemicals) (1)

    filter

    01 SORAFENIB HEMITOSYLATE (1)

    filter

    01 Canada (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    DELMAR CHEMICALS INC

    Contact Supplier
    • FDA
    Virtual BoothMinakem is manufacturing small molecules APIs including corticosteroids
    Contact Supplier Contact Supplier
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    SORAFENIB HEMITOSYLATE

    PDF Supplier PDF
    URL Supplier Web Content
    32140
    Active
    2017-12-20
    Complete
    2018-07-27
    2018-01-19
    II
    Minakem Delmar

    CPhI Japan

    Not Confirmed

    envelop Contact Supplier

    Looking for Drug Master Files (DMF) for 32140 of Delmar Chemicals Inc

    Looking for Drug Master Files (DMF) for 32140 of Delmar Chemicals Inc 1

    20

    Delmar Chemicals Inc, based in Canada, is a pharmaceutical company that stands out with its certifications from FDA.

    They are recognized for Minakem is manufacturing small molecules APIs including corticosteroids

    One of their notable products is SORAFENIB HEMITOSYLATE, with a corresponding US DMF Number 32140.

    Remarkably, this DMF maintains an Active status since its submission on December 20, 2017, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of July 27, 2018, and payment made on January 19, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY